Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATEA PHARMACEUTICALS, INC.

(AVIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Atea Pharma Hits Development Milestone for Covid-19 Treatment

06/16/2021 | 07:42am EDT

By Chris Wack

Atea Pharmaceuticals Inc. said it has achieved a milestone associated with the development of AT-527, and expects to receive a related payment under its license agreement with Roche of $50 million.

Under the license agreement, Roche and Atea are jointly developing AT-527 for the treatment of Covid-19.

AT-527 is an orally administered, direct-acting antiviral developmental agent derived from Atea's purine nucleotide pro-drug platform, and it is in Phase 3 development for the treatment of Covid-19, Atea said.

Atea retains rights to commercialize AT-527 in the U.S., and Roche has the exclusive right to commercialize AT-527 outside the U.S.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

06-16-21 0741ET

Stocks mentioned in the article
ChangeLast1st jan.
ATEA PHARMACEUTICALS, INC. -4.49% 26.59 Delayed Quote.-36.36%
ROCHE HOLDING AG 0.35% 354 Delayed Quote.14.16%
All news about ATEA PHARMACEUTICALS, INC.
07/23ATEA PHARMACEUTICALS : Sublease Agreement, dated as of July 19, 2021, by and bet..
PU
07/23ATEA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Creatio..
AQ
07/20PRESS RELEASE : Japan becomes first country to approve Ronapreve (casirivimab an..
DJ
07/12Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference
GL
06/30ROCHE : Atea Says Oral COVID-19 Drug Developed With Roche Reduces Viral Load in ..
MT
06/30SECTOR UPDATE : Health Care Stocks Slip Premarket Wednesday
MT
06/30ATEA PHARMACEUTICALS : Says Anti-Viral Drug Showed Positive Results in COVID-19 ..
MT
06/30Atea Pharma Reports Encouraging Results From Study of Covid-19 Treatment
DJ
06/30Atea's AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in..
GL
06/30Atea Pharmaceuticals, Inc. Announces Positive Interim Results from the Global..
CI
More news
Financials (USD)
Sales 2021 294 M - -
Net income 2021 46,1 M - -
Net cash 2021 686 M - -
P/E ratio 2021 53,7x
Yield 2021 -
Capitalization 2 200 M 2 200 M -
EV / Sales 2021 5,16x
EV / Sales 2022 0,28x
Nbr of Employees 42
Free-Float 81,5%
Chart ATEA PHARMACEUTICALS, INC.
Duration : Period :
Atea Pharmaceuticals, Inc. Technical Analysis Chart | AVIR | US04683R1068 | MarketScreener
Technical analysis trends ATEA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 26,59 $
Average target price 57,00 $
Spread / Average Target 114%
EPS Revisions
Managers and Directors
Jean-Pierre Sommadossi Chairman, President & Chief Executive Officer
Andrea J. Corcoran Chief Financial Officer, Secretary & EVP-Legal
Maria Arantxa Horga Chief Medical Officer
Keith Pietropaolo Senior Vice President-Clinical Operations
Claudio Avila Senior Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ATEA PHARMACEUTICALS, INC.-36.36%2 303
GILEAD SCIENCES, INC.17.32%87 579
BIONTECH SE331.56%84 970
WUXI APPTEC CO., LTD.41.52%71 929
REGENERON PHARMACEUTICALS19.46%60 737
VERTEX PHARMACEUTICALS-15.36%51 899